Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Autor: Timothy J. Vreeland, Chad A. Hamilton, John S. Berry, Kathleen M. Darcy, George E. Peoples, Garth S. Herbert, Kevin Byrd, Jonathan W. Martin, Tommy A. Brown, Julia M. Greene, Diane F. Hale, George L. Maxwel, Guy T. Clifton, John W. Myers, Doreen O. Jackson, John C. Elkas, Thomas P. Conrads
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Cancer Research
medicine.medical_treatment
Primary disease
Gastroenterology
FBP
0302 clinical medicine
vaccine
Prospective Studies
Original Research
Ovarian Neoplasms
Folate Receptors
GPI-Anchored
Middle Aged
Immunogenic peptide
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Treatment Outcome
ovarian cancer
Oncology
030220 oncology & carcinogenesis
Vaccines
Subunit
endometrial cancer
Female
immunotherapy
medicine.medical_specialty
Immunization
Secondary
Cancer Vaccines
lcsh:RC254-282
03 medical and health sciences
Internal medicine
HLA-A2 Antigen
medicine
Humans
Radiology
Nuclear Medicine and imaging
Aged
Dose-Response Relationship
Drug
business.industry
Endometrial cancer
E39
Granulocyte-Macrophage Colony-Stimulating Factor
Clinical Cancer Research
Immunotherapy
medicine.disease
Survival Analysis
Folate-binding protein
Endometrial Neoplasms
030104 developmental biology
Landmark analysis
Peptide vaccine
Neoplasm Recurrence
Local
business
Ovarian cancer
Zdroj: Cancer Medicine, Vol 8, Iss 10, Pp 4678-4687 (2019)
Cancer Medicine
ISSN: 2045-7634
Popis: Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of either E39 or E39′ (an attenuated version of E39) to prevent recurrences in disease‐free endometrial and ovarian cancer patients(pts). Here, we present the final 24‐month landmark analysis. Patients and methods HLA‐A2 + patients receiving E39 + GM‐CSF were included in the vaccine group (VG), and HLA‐A2‐ pts (or HLA‐A2 + patients refusing vaccine) were followed as the control group (CG). VG group received 6 monthly inoculations as the primary vaccine series (PVS) and were randomized to receive either E39 or E39′ booster inoculations. Demographic, safety, immunologic, and disease‐free survival (DFS) data were collected and evaluated. Results Fifty‐one patients were enrolled; 29 in the VG and 22 in the CG. Fourteen patients received
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje